薬剤溶出ステントの世界市場：規模、シェア、COVID-19の影響分析（2023年～2029年）：MedCore

世界の薬剤溶出ステントの市場規模は、2022年に1億560万米ドルとなりました。同市場は予測期間中に1.8％のCAGRで拡大し、1億1,960万米ドルに達すると予測されています。

当レポートでは、世界の薬剤溶出ステント市場について調査し、市場の概要とともに、セグメント別、地域別動向、競合情勢などを提供しています。

目次

薬剤溶出ステント市場

• イントロダクション
• 市場分析と予測
• 促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 競合市場シェア分析

LIST OF CHARTS

• Chart 12-1: Drug-Eluting Stent Market, U.S., 2019 - 2029

LIST OF FIGURES

• Figure 12-1: Drug-Eluting Stent Market, U.S., 2019 - 2029
• Figure 12-2: Leading Competitors, Drug-Eluting Stent Market, U.S., 2022

The global market for drug-eluting stents had a valuation of $105.6 million in 2022, and it is projected to grow at a CAGR of 1.8% during the forecast period, reaching $119.6 million. The comprehensive report on the market focuses solely on drug-eluting stents and does not include its extended set.

MARKET DATA INCLUDED:

• Unit Sales, Average Selling Prices, Market Size & Growth Trends

• Procedure Numbers

• COVID-19 Impact Analysis

• Market Drivers & Limiters

• Market Forecasts Until 2029, and Historical Data to 2019

• Recent Mergers & Acquisitions

• Company Profiles and Product Portfolios

• Leading Competitors

GLOBAL DRUG-ELUTING STENT MARKET INSIGHTS

The primary driver of the drug-eluting stent market is the lack of competition. Intersect ENT is the sole competitor in the market, which enables the company to maintain higher selling prices, driving up the market value. The company's monopoly on the market is a significant factor in the growth of the drug-eluting stent market.

GLOBAL DRUG-ELUTING STENT MARKET SHARE INSIGHTS

The Global drug-eluting stent market was led by Intersect ENT.

Intersect ENT dominates the drug-eluting stent market with its Propel® family of products. These stents are designed to be used in combination with ethmoid sinus surgery, with different shapes and sizes available to suit different sinus anatomies. The company's product line also includes Sinuva® Sinus Implant, which is used to treat nasal polyps in patients who have undergone previous ethmoid sinus surgery. Both Propel® and Sinuva® implants release the corticosteroid mometasone furoate.

MARKET SEGMENTATION SUMMARY

ENT Drug-Eluting Stent Market - MedCore

RESEARCH SCOPE SUMMARY

• Regions: North America (Canada, United States), Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela), Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, U.K.), Central & Eastern Europe (Baltic States, Bulgaria, Croatia, Czech Republic, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Turkey, Ukraine), Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates), Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam), Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda)

• Base Year: 2022
• Forecast Period: 2023-2029
• Historical Data: 2019-2022

• Quantitative Data: Market Size, Market Share, Market Growth Rates, Units Sold, Average Selling Prices

• Qualitative Data: COVID-19 Impact, Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios

• Data Sources: Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data.

Read more about iData's 9-Step Research Methodology.

Table of Contents

Drug-Eluting Stent Market

• 12.1 Introduction
• 12.2 Market Analysis and Forecast
• 12.3 Drivers and Limiters
  • 12.3.1 Market Drivers
  • 12.3.2 Market Limiters
• 12.4 Competitive Market Share Analysis